Tumor risk by tissue engineering: cartilaginous differentiation of mesenchymal stem cells reduces tumor growth

Osteoarthritis and Cartilage

Volumn 18, Issue 3, 2010, Pages 389-396

  Akay, I ^a   Oxmann, D ^a   Helfenstein, A ^a   Mentlein, R ^a   Schunke M ^a   Hassenpflug, J ^b   Kurz, B ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

ACI; Cartilage; Cell labeling; MSC; Tissue engineering; Tumor growth

Indexed keywords

GREEN FLUORESCENT PROTEIN;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RISK; CARTILAGE; CELL DIFFERENTIATION; CELL ISOLATION; CELL LABELING; CELL MIGRATION; CONTROLLED STUDY; GENETIC TRANSDUCTION; MELANOMA; MESENCHYMAL STEM CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; TISSUE DIFFERENTIATION; TISSUE ENGINEERING; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CHONDROCYTES; EAR CARTILAGE; GREEN FLUORESCENT PROTEINS; LUMINESCENT AGENTS; MELANOMA, EXPERIMENTAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; NEOPLASMS; RISK FACTORS;

EID: 76549097368     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2009.10.015     Document Type: Article

References (44)

1. Brittberg M. Autologous chondrocyte implantation-technique and long-term followup. Injury 39 (2008) S40-S49
2. Coleman S.H., Malizia R., Macgillivray J., and Warren R.F. Treatment of isolated articular cartilage lesions of the medial femoral condyle. A clinical MR comparison of autologous chondrocyte implantation vs. microfracture. Ortop Traumatol Rehabil 30 (2001) 224-226
3. Dickhut A., Gottwald E., Steck E., Heisel C., and Richter W. Chondrogenesis of mesenchymal stem cells in gel-like biomaterials in vitro and in vivo. Front Biosci 13 (2008) 4517-4528
4. Jorgensen C., Djouad F., Bouffi C., Mrugala D., and Noël D. Multipotent mesenchymal stromal cells in articular diseases. Best Pract Res Clin Rheumatol 22 (2008) 269-284
5. Yan H., and Yu C. Repair of full-thickness cartilage defects with cells of different origin in a rabbit model. Arthroscopy 23 (2007) 178-187
6. Freitas C.S., and Dalmau S.R. Multiple sources of non-embryonic multipotent stem cells: processed lipoaspirates and dermis as promising alternatives to bone-marrow-derived cell therapies. Cell Tissue Res 325 (2006) 403-411
7. Mageed A.S., Pietryga D.W., DeHeer D.H., and West R.A. Isolation of large numbers of mesenchymal stem cells from the washings of bone marrow collection bags: characterization of fresh mesenchymal stem cells. Transplantation 83 (2007) 1019-1026
8. Lu L.L., Liu Y.J., Yang S.G., Zhao Q.J., Wang X., Gong W., et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 91 (2006) 1017-1026
9. Wexler S.A., Donaldson C., Denning-Kendall P., Rice C., Bradley B., and Hows J.M. Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol 121 (2003) 368-374
10. Barry F.P., Boynton R.E., Haynesworth S., Murphy M., and Zaia J. The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Commun 265 (1999) 134-139
11. Deans R.J., and Moseley A.B. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 28 (2000) 875-884
12. Noel D., Djouad F., and Jorgensen C. Regenerative medicine through mesenchymal stem cells for bone and cartilage repair. Curr Opin Investig Drugs 3 (2002) 1000-1004
13. Brooke G., Tong H., Levesque J.P., and Atkinson K. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cell Dev (2008) 18
14. Valtieri M., and Sorrentino A. The mesenchymal stromal cell contribution to homeostasis. J Cell Physiol 217 2 (2008 Nov) 296-300
15. Zhao L., Li G., Chan K.M., Wang Y., and Tang P.F. Comparison of multipotent differentiation potentials of murine primary bone marrow stromal cells and mesenchymal stem cell line C3H10T1/2. Calcif Tissue Int 84 1 (2009 Jan) 56-64
16. Le Blanc K., Rasmusson I., Sundberg B., Götherström C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
17. Le Blanc K., Samuelsson H., Gustafsson B., Remberger M., Sundberg B., Arvidson J., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21 (2007) 1733-1738
18. Devine S.M., Bartholomew A.M., and Mahmud N. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 29 (2001) 244-255
19. Rombouts W.J., and Ploemacher R.E. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 17 1 (2003 Jan) 160-170
20. Gao J., Dennis J.E., Muzic R.F., Lundberg M., and Caplan A.I. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169 1 (2001) 12-20
21. Kinlen L.J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78 (1985) 44-49
22. Ondrus D., Pribylincová V., Breza J., Bujdák P., Miklosi M., Reznícek J., et al. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy. Int Urol Nephrol 31 (1999) 417-422
23. Fortina A.B., Piaserico S., Caforio A.L., Abeni D., Alaibac M., Angelini A., et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol 140 (2004) 1079-1085
24. Caforio A.L., Fortina A.B., Piaserico S., Alaibac M., Tona F., Feltrin G., et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 102 (2000) III222-III227
25. Zhu W., Xu W., Jiang R., Qian H., Chen M., Hu J., et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 80 (2006) 267-274
26. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102 (2003) 3837-3844
27. Dressel R., Schindehütte J., Kuhlmann T., Elsner L., Novota P., Baier P.C., et al. The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PLoS ONE 3 (2008) e2622
28. Baker D.E., Harrison N.J., Maltby E., Smith K., Moore H.D., Shaw P.J., et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol 25 (2007) 207-215
29. Nakamura K., Yoshikawa N., Yamaguchi Y., Kagota S., Shinozuka K., and Kunitomo M. Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model. Life Sci 70 (2002) 791-798
30. Lorens J.B., Bennett M.K., Pearsall D.M., Throndset W.R., Rossi A.B., Armstrong R.J., et al. Retroviral delivery of peptide modulators of cellular functions. Mol Ther 5 (2000) 438-447
31. Kurz B., Domm C., Jin M., Sellckau R., and Schünke M. Tissue engineering of articular cartilage under the influence of collagen I/III membranes and low oxygen tension. Tissue Eng 10 (2004) 1277-1286
32. Domm C., Schünke M., Christesen K., and Kurz B. Redifferentiation of dedifferentiated bovine articular chondrocytes in alginate culture under low oxygen tension. Osteoarthritis Cartilage 10 1 (2002 Jan) 13-22
33. Preira R.F., Halford K.W., and O'Hara M.D. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage and lung in irradiated mice. Proc Natl Acad Sci USA 92 (1995) 4857-4861
34. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., and Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57 (2003) 11-20
35. Svennilson J. Novel approaches in GVHD therapy. Bone Marrow Transplant 35 (2005) S65-S67
36. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 (2002) 3838-3843
37. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30 (2002) 42-48
38. Satzger I., Schenck F., Kapp A., and Gutzmer R. Spontaneous regression of melanoma with distant metastases - report of a patient with brain metastases. Eur J Dermatol 16 (2006) 454-455
39. Francis A., Temple J.G., and Hallissey M.T. Spontaneous resolution of histologically proven liver metastases from colorectal cancer. Br J Surg 84 (1997) 818
40. Cafferata M.A., Chiaramondia M., Monetti F., and Ardizzoni A. Complete spontaneous remission of non-small-cell lung cancer: a case report. Lung Cancer 45 (2004) 263-266
41. Horii R., Akiyama F., Kasumi F., Koike M., and Sakamoto G. Spontaneous "healing" of breast cancer. Breast Cancer 12 (2005) 140-144
42. Blattman J.N., and Greenberg P.D. Cancer immunotherapy: a treatment for the masses. Science 305 (2004) 200-205
43. Stripecke R., Carmen Villacres M., Skelton D., Satake N., Halene S., and Kohn D. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 6 (1999) 1305-1312
44. Hadaczek P., Forsayeth J., Mirek H., Munson K., Bringas J., Pivirotto P., et al. Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther 20 3 (2009 Mar) 225-237